NICE has recommended durvalumab for NHS use in England as part of perioperative treatment for adults with resectable gastric or gastro-oesophageal junction adenocarcinoma.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/nice-backs-first-immunotherapy-resectable-gastric-cancer-2026a1000frm?src=rss
Author :
Publish date : 2026-05-15 09:49:00
Copyright for syndicated content belongs to the linked Source.
